A second look at heart death data from a major drug trial found more heart-related deaths in the treatment group than were first reported, while the placebo group had fewer — suggesting the original...
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
A second look at heart death data from a major drug trial found more heart-related deaths in the treatment group than were first reported, while the placebo group had fewer — suggesting the original...
See the technical phrasing
Independent readjudication of cause-of-death data from the FOURIER trial indicates that myocardial infarction-related deaths were undercounted in the evolocumab group, with 36 deaths identified compared to 25 originally reported, while the placebo group's myocardial infarction deaths decreased from 30 to 27, revealing a discrepancy in cardiovascular mortality reporting between the Clinical Study Report and the original 2017 NEJM publication.
What the research says
Supports
1 study
Study: Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies